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Abstract: Cholesterol regulation is an important aspect of human health. In this work we bring
together and extend two recent mathematical models describing cholesterol biosynthesis and
lipoprotein endocytosis to create an integrated model of lipoprotein metabolism in the context
of a single hepatocyte. The integrated model includes a description of low density lipoprotein (LDL)
receptor and cholesterol synthesis, delipidation of very low density lipoproteins (VLDLs) to LDLs and
subsequent lipoprotein endocytosis. Model analysis shows that cholesterol biosynthesis produces
the majority of intracellular cholesterol. The availability of free receptors does not greatly effect
the concentration of intracellular cholesterol, but has a detrimental effect on extracellular VLDL
and LDL levels. We test our model by considering its ability to reproduce the known biology of
Familial Hypercholesterolaemia and statin therapy. In each case the model reproduces the known
biological behaviour. Quantitative differences in response to statin therapy are discussed in the
context of the need to extend the work to a more in vivo setting via the incorporation of more dietary
lipoprotein related processes and the need for further testing and parameterisation of in silico models
of lipoprotein metabolism.
Keywords: ordinary differential equation; SREBP-2
1. Introduction
Cholesterol is an intrinsic part of living cells. Every cell in the human body requires cholesterol in
order to produce and maintain a healthy cell membrane. The formation of hormones and of bile acids
that assist in the digestion of food, depend on cholesterol. Myelin, which covers nerve axioms to assist
the conduction of electrical impulses, facilitating movement, vision, taste and the processing of sensory
input is 20%, by weight, cholesterol [1]. This makes cholesterol vital for our nervous system and for
memory and learning to take place. All cells have the ability to produce and regulate cholesterol,
but the liver is primarily responsible for the metabolism of dietary cholesterol and is the only organ
that can remove it from the body via the formation of bile.
Despite being such an important part of cellular health, irregular control of cholesterol homeostasis
in hepatocytes (liver cells) can cause the liver to poorly process dietary cholesterol. This in turn can
lead to high levels of circulating plasma cholesterol, which is widely known to be a major risk factor
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for a large number of cardiac diseases, for example coronary artery disease (CAD), cardiovascular
disease (CVD) and coronary heart disease (CHD). The chance of developing CAD, CVD or CHD is
determined by risk factors, some of which are modifiable. Modifiable risk factors include body weight,
blood pressure and blood lipid levels, which are all influenced by exercise levels, smoking and diet.
Non-modifiable risk factors include genetic predisposition, age, gender and ethnicity [2]. Whilst we
may not be able to control these factors, the effects are sometimes modifiable with pharmaceutical
interventions such as statins.
Dietary or exogenous cholesterol however, accounts for merely 20% of the body’s cholesterol.
The other 80%, endogenous cholesterol, is produced mainly by hepatocytes, but also by cells in
the central nervous system and reproductive organs [3]. Each cell is subject to the cholesterol
biosynthesis cascade initiated by 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR).
This signalling pathway cues the change in rate of production or inhibition of cholesterol in response to
declining or increasing cellular cholesterol levels. In this case the transcription factor, sterol regulatory
element-binding protein 2 (SREBP-2), is blocked from upregulating mRNA transcription of the HMGCR
gene when cellular levels of cholesterol are high, but is free to upregulate transcription when levels are
low. This allows the cell to change the rate of cholesterol production according to its needs.
Fats and cholesterol from a normal diet enter the blood stream, through the stomach, having been
packed into carrier molecules known as a lipoproteins. Lipids are insoluble and must thus be
packed into particles in order to be transported around the body. Lipoproteins are surrounded
by phospholipids and apolipoproteins. As well as surrounding lipoprotein molecules, apolipoproteins
play a vital role in the binding of lipoproteins to receptors on cell surfaces for removal from circulation.
They also act as activators for lipolytic enzymes involved in metabolism.
There are five main classes of lipoprotein: chylomicrons, very low density lipoproteins (VLDL),
intermediate density lipoprotein (IDL), low density lipoprotein (LDL) and high density lipoprotein
(HDL). They are classed due to their varying triglyceride, cholesterol and apolipoprotein contents.
Lipoproteins continuously exchange lipids and proteins with cells and other lipoproteins leading to a
reduction in lipid content as the particles vary from being chylomicrons, to chylomicron remnants,
VLDL, IDL and subsequently LDL particles.
Carrying fats as an energy source through the blood stream to cells in need, lipoproteins eventually
end up in the liver where they are removed from circulation by a process known as receptor mediated
endocytosis (RME). The rate of lipoprotein uptake is regulated by the number of available free receptors
on the cell surface. Receptors are synthesised by the cell. Newly synthesised receptors are placed on
the surface of the cell where they collect in clathrin coated pits. Apolipoproteins attach the lipoprotein
to the receptor, after which the clathrin pit encloses around the lipoprotein and pinches off forming
endocytotic vesicles which are internalised. Empty pits may also undergo this process. Following
internalisation, the clathrin coating is shed and vesicles merge together to form larger endosomes
within which the lipoprotein dissociates from the receptor. Some receptors are removed at this point
and recycled to the cell surface. The endosomes then combine with lysosomes within the cell and the
contents are degraded by lysosomal enzyme hydrolysis releasing amino acids and cholesterol for use
in cellular metabolism [4].
Receptors, once synthesised or recycled, insert randomly on the cell surface before diffusing into
clathrin coated pits. The concentration of receptors in the pits determine how many lipoproteins
can bind and be internalised at any one time. LDL receptor (LDLR) synthesis is governed by
SREBP-2. When intracellular cholesterol concentrations are low transcription of LDLR is upregulated,
increasing the uptake of lipoproteins. Similarly high levels of cholesterol lead to downregulation of
LDLR synthesis, decreasing lipoprotein endocytosis. In high cholesterol concentrations, receptor and
cholesterol synthesis is inhibited. RME is the target of drugs, used in cardiovascular therapy, known as
statins which inhibit cholesterol biosynthesis and up-regulate receptor synthesis, thus increasing the
amount of lipoproteins cleared from the circulation.
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Dysregulated cholesterol biosynthesis and lipoprotein metabolism can lead to a number of health
conditions. Dyslipidemia, raised levels of LDL in blood plasma and/or reduced levels of high density
lipoprotein (HDL), is a major health issue throughout the world [5], which has been linked to increases
in dietary fat and sugar intake and sedimentary lifestyles. Hypercholesterolemia, elevated levels of
cholesterol in blood plasma, has been linked to cardiovascular and pulmonary inflammation [6] and
the overloading of macrophages with cholesterol in vitro has been shown to initiate immune responses.
In contrast, unduly lowering the biosynthetic production of cholesterol levels, such as more recently
shown via pathogenic infections which may lead to sepsis, can have dramatic adverse results [7,8].
There exists a growing literature on the mathematical modelling of lipoprotein metabolism as
recently reviewed in [9]. Such models have generally been formulated using the theory of linear and
nonlinear ordinary differential equations and parameterised and tested, to varying degrees, against
the experimental literature. The mathematical models reviewed in [9] were tested for their ability to
correctly predict the response of each to statin therapy. They found that only a small proportion of
models within the literature correctly predicted the well known effect of statins on increasing LDL
uptake from the circulation.
In contrast there are few mathematical models of cholesterol biosynthesis. Those that do exist
vary in the size of the mathematical models formulated (number of variables and parameters) and
complexity. In [10] the authors derived, parameterised and analysed a three variable nonlinear
ordinary differential equation (ODE) model of cholesterol biosynthesis via the HMGCR pathway.
They demonstrated that whilst the system only exhibited one steady-state, three types of behaviour
were possible; monotic, damped and oscillatory. A more recent ODE model of the mevalonate pathway
has been formulated and analysed in detail by [11]. This model describes cholesterol biosynthesis via
the HMGCR and squalene synthase pathways, demonstrates the effect of the cholesterol-SREBP-2
feedback on the network’s temporal responses, whilst more localised positive feedbacks within the
network ensure cholesterol levels remained tightly bound should any products within the pathway be
adversely increased or decreased.
Limited work has focused on integrating molecular scale cholesterol synthesis with lipoprotein
endocytosis and LDLR synthesis. One exception is that of the unpublished work of [12],
which integrated a description of LDL endocytosis [13] with that of cholesterol biosynthesis [10].
This was favourably evaluated by [9] in assessing how well the model reproduced the known cellular
response to statins, but no mathematical or computational analysis of the model was undertaken.
In this work we present a model of integrated cholesterol biosynthesis, which includes a
description of SREBP-2 regulation by cholesterol (as detailed in [14]), a full description of VLDL
and LDL uptake (as detailed in [15]) coupled with a description of receptor biosynthesis. The work
provides a full account of model formulation, analysis and testing thereof. We are motivated by
the following considerations. Firstly, we wish to develop a well-informed integrated mathematical
model of the core exogenous and endogenous cholesterol pathways within a hepatocyte. We wish
to evaluate whether a simplified model formulated in an in vitro context can capture the known in
vivo biological response of the system in respect of Familial Hypercholesterolaemia and statin therapy,
without having to complicate the model by accounting for other in vivo aspects (for instance HDL,
chylomicron remnants, VLDL hepatocyte recycling). Secondly, we wish to consider how rates of VLDL
to LDL delipidation coupled with competition between the two particles for cell membrane level
receptors may affect intracellular cholesterol levels. High levels of circulating LDL is an indicator of
risk in a number cardiovascular diseases and one of the main sources of circulating LDL is delipidation.
Because of this we have included VLDL to LDL delipidation in this model in order to explore it’s effects
without the complication of a full description of dietary lipoprotein metabolism. Finally, we wish to
evaluate any differences that the assumption of a continuum of receptors on the surface of a cell has
(as per [15]) versus that of discrete description of receptors bound by differing numbers of VLDL and
LDL particles (as per [13]).
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Our paper is organised as follows. In Section 1.1 we discuss the main biological features included
in our integrated mathematical model before presenting an ODE model of the system in Section 2.1.
Details of the model parameterisation are discussed in Section 2.4, which is followed by numerical
simulations of the governing system of equations in Section 3.1. Results of computational and
mathematical model analysis are presented in Section 3.2, before we investigate the effect of different
classes of FH on extracellular levels of LDL and intracellular cholesterol levels. The effect of varying
levels of statin therapy are investigated in Section 3.4 before we summarise and discuss our findings in
Section 4.
Whilst our model has been formulated and parameterised in an in vitro context, the extrapolation
to an in vivo setting is not considerably different given hepatocytes will be surrounded by lipoproteins
within the liver. We thus wish to test how well this extrapolation works by testing the model against
known in vivo outcomes in respect of Familial Hypercholesterolaemia and response to statin therapy.
1.1. Cholesterol Biosynthesis and Lipoprotein Metabolism
Our work here couples the endocytosis model of VLDL and LDL metabolism in an hepatocyte
described in [15] with the description of cholesterol biosynthesis detailed in [10] and extends it with
descriptions of LDLR synthesis, VLDL uptake and VLDL to LDL delipidation. An overview of the
main processes included in our model is given in Figure 1 with further details on the exact mechanisms
provided in Figure 2.
Figure 1. An overview of the main features included in our integrated mathematical model of
cholesterol and receptor biosynthesis coupled with lipoprotein (VLDL and LDL) endocytosis.
While the model described in this work extends previous descriptions of in vitro lipoprotein
endocytosis, it has not been formulated with a specific in vitro cell experiment in mind, as was the
case in [15]. Instead it seeks to describe relevant processes at the subcellular and extracellular scale,
which can be found both in vitro and in vivo, thus providing a means of extrapolating between the
two. We assume concentrations of VLDL and LDL are fed to hepatocytes in a controlled manner,
thereby describing the basic mechanisms of cholesterol synthesis and LDL and VLDL metabolism
without the added complexity of describing other dietary lipoprotein metabolism.
These two models have been individually parameterised, analysed and their behaviour tested
against published in vitro experimental data as detailed in each publication [10,15]. The integrated
model consists of three main compartments: (i) the cell nucleus in which genetic regulation of HMGCR
and LDLR occurs; (ii) the cell cytoplasm surrounded by the cell membrane in which all processes
related to VLDL and LDL binding and breakdown, cell receptor and cholesterol regulation take
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place; and (iii) the extracellular space around the cell containing sources of VLDL and LDL, as shown
in Figure 2. Whilst full details on each of the mathematical models can be found in each of the
respective references, we provide here a summary of the main processes incorporated into the model
for completeness, along with descriptions of the additional processes required for an integrated model.
To ensure these mechanisms are clear in the context of the mathematical formulation presented in
Section 2.1, we define the respective model variables as each mechanism is discussed. Parameter values
associated with each process are detailed in Figure 2 and Table 1.
Figure 2. Our integrated model of cholesterol biosynthesis and lipoprotein endocytosis in a hepatocyte.
Transcription of HMGCR and LDLR mRNA (at rates µmh and µmr, respectively) by SREBP-2 (κmh, κmr),
leads to the synthesis of HMGCR (µh), LDLR (µr) and cholesterol (µc), which negatively regulates
SREBP-2 (κc). In the extracellular space, VLDL delipidates to LDL (χv) and each bind/unbind to LDLR
on the cell surface (αv, α−v, αL, α−L). Finally VLDL and LDL occupied receptor pits are endocytosed
(βV , βL) as well as empty ones (β0), cholesterol extracted from internalised lipoproteins (γv and γL)
and receptors recycled in the intracellular space ( f ,γr). Here mh represents HMGCR mRNA, mr LDLR
mRNA, H HMGCR, RI receptors in the internal store, c intracellular cholesterol and φ degradation of
the respective entity.
At the genetic level SREBP-2 transcribes the HMGCR gene to produce HMGCR mRNA, HMGCR
and cholesterol (at rates µ¯mh, µ¯h and µ¯c respectively) as described in [10]. Our integrated model also
requires a description of LDLR synthesis as a result of SREBP-2 transcription which is described by the
following biochemical equation
Gr + xrS
κ¯mr−−⇀↽ −
κ¯−mr
Sbr
µ¯mr−−−−→ Mr
µ¯r−−−−→ RI , (1)
where unbound free LDLR gene is represented by Gr, free SREBP-2 is represented by S and Sbr
represents SREBP-2 bound to the LDLR gene. Once SREBP-2 and the LDLR gene become bound
transcription of LDLR mRNA, Mr is upregulated and accordingly, translation of the mRNA to create
receptors, RI occurs. These are placed in the internal receptor store of the cell, assumed to be in the
cell cytoplasm.
The reaction rate constants of κ¯mr represent SREBP-2 binding to the LDLR free gene, whilst κ¯−mr
represents the reaction rate of SREBP-2 unbinding from the LDLR gene. Here xr is the number of
binding sites on the LDLR gene SREBP-2 binds to. The rate of transcription of mRNA responsible for
receptor synthesis is µ¯mr and µ¯r is the rate of translation of LDLR from LDLR mRNA.
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The incorporated mechanisms of VLDL and LDL endocytosis and their respective dynamics
at the cellular level are as follows. LDL particles in the medium surrounding the cell (denoted
lE) bind to free receptors (rF) in clathrin pits on the cell surface at rate α¯L and unbind at rate α¯−L.
In binding, LDL particles effectively bind to one receptor, but can occlude up to ml surrounding
receptors. The bound receptor and LDL (lRB) and the free and occluded receptors in the pit are then
internalised (at rate β¯L) to become internalised vesicles (l I).
Internalised vesicles and their contents subsequently break down whereby the cholesterol c
contained within the LDL particles is added to the internal cholesterol pool of the cell (γ¯L), where it is
esterified for other cellular processes at a rate proportional to it’s concentration (δ¯c). A proportion f of
the free receptors in the vesicle are placed in the cells internal cell store, ready for recycling back to the
cell surface (γ¯r). The rest are degraded.
VLDL particle binding, internalisation and subsequent breakdown are governed by a similar series
of processes represented by variables denoted with v instead of l, for example vE for the concentration
of extracellular VLDL and α¯v for binding of VLDL to receptors. Pits consisting of P empty receptors
(no LDL or VLDL bound) may also be internalised β¯0.
Further to these processes, VLDL supply to the serum and VLDL to LDL delipidation is
described by
ω¯ −−−−→ VE
χ¯v−−−−→ LE, (2)
where ω¯ is a constant supply of VLDL to the serum and χ¯v is the respective reaction rate constant
of delipidation.
2. Materials and Methods
2.1. Mathematical Formulation
Applying the Law of Mass Action to those mechanisms described in Section 1.1 coupled with
the models of [10,15] leads to the system of Equations (3)–(20), that integrate cholesterol and receptor
biosynthesis with lipoprotein metabolism metabolism.
Biosynthesis of cholesterol and LDLR via SREBP-2 are described by
dg¯h
dt¯
= (κ¯−mh s¯bh − κ¯mh s¯xh g¯h), (3)
dg¯r
dt¯
= (κ¯−mr s¯br − κ¯mr s¯xr g¯r), (4)
ds¯
dt¯
= (xhκ¯−mh s¯bh − xhκ¯mh s¯xh g¯h + xrκ¯−mr s¯br − xrκ¯mr s¯xr g¯r − κ¯c c¯xc s¯+ κ¯−c c¯b), (5)
ds¯bh
dt¯
= (−κ¯−mh s¯bh + κ¯mh s¯xh g¯h), (6)
ds¯br
dt¯
= (−κ¯−mr s¯br + κ¯mr s¯xr g¯r), (7)
J
dm¯h
dt¯
= µ¯mh s¯bh − δ¯mhm¯h, (8)
J
dm¯r
dt¯
= µ¯mr s¯br − δ¯mrm¯r, (9)
dh¯
dt¯
= µ¯hm¯h − δ¯h h¯, (10)
where the time dependent variables represent concentrations of each of the respective entities detailed
in Figure 2, such that g¯h is the concentration of free HMGCR gene, g¯r that of LDLR gene, s¯ is free
unbound SREBP-2, s¯bh is SREBP-2 bound to the HMGCR gene, s¯br is SREBP-2 bound to the LDLR gene,
m¯h is the concentration of HMGCR mRNA, m¯r is that of LDLR mRNA and h¯ is HMGCR. We note that
xc is the number of binding sites for cholesterol to bind to SREBP-2, xr is the number of binding sites
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on the LDLR gene for SREBP to bind to and xh is the number of binding sites on the HMGCR gene to
which SREBP binds.
The mechanisms of LDL and VLDL endocytosis and the subsequent processing of cholesterol and
receptors, is given by the following
W
dl¯E
dt¯
= −α¯L r¯ f l¯E + α¯−L l¯RB +W(χ¯vv¯E), (11)
dl¯RB
dt¯
= α¯L r¯ f l¯E − α¯−L l¯RB − β¯L l¯RB, (12)
dl¯I
dt¯
= β¯L l¯RB − γ¯L l¯I , (13)
W
dv¯E
dt¯
= −α¯v r¯ f v¯E + α¯−vv¯RB +W(−χ¯vv¯E + ω¯), (14)
dv¯RB
dt¯
= α¯v r¯ f v¯E − α¯−vv¯RB − β¯vv¯RB, (15)
dv¯I
dt¯
= β¯vv¯RB − γ¯vv¯I , (16)
dr¯ f
dt¯
= γ¯r r¯I − Pβ¯0r¯Pf − m˜l β¯L l¯RB −ml α¯L l¯E r¯ f +ml α¯−L l¯RB − m˜v β¯vv¯RB −mvα¯vv¯E r¯ f
+mvα¯−vv¯RB, (17)
dr¯I
dt¯
= µ¯rm¯r − γ¯r r¯I + P f β¯0r¯Pf + f (ml + m˜l)β¯L l¯RB + f (mv + m˜v)β¯vv¯RB, (18)
dc¯
dt¯
= RcholL γ¯L l¯I + R
chol
v γ¯vv¯I + µ¯c h¯− δ¯c c¯+ J(xcκ¯−c c¯b − xcκ¯c c¯xc s¯), (19)
dc¯b
dt¯
= (κ¯c c¯xc s¯− κ¯−c c¯b), (20)
where the concentration of free LDL surrounding the cell is l¯E, l¯RB is receptor bound LDL, l¯I is
internalised LDL, v¯E is free VLDL surrounding the cell, v¯RB is receptor bound VLDL, v¯I is internalised
VLDL, r¯ f are free unbound receptors, r¯I are internalised receptors, c¯ is cholesterol and c¯b is the SREBP-2
cholesterol bound complex.
Equations (3)–(9) and (20) describe the synthesis of HMGCR mRNA and LDLR mRNA via
SREBP-2 as regulated by cholesterol (Equation (19)). Equation (10) describes the production of
HMGCR from HMGCR mRNA while production of LDLR, which are assumed to automatically join
the internal receptor store, is accounted for in equation (18). Equations (11)–(20) are essentially those as
detailed in [15] with the addition of the respective genetic synthesis terms describing cholesterol
and LDLR production. Equations (11) and (14) detail the association of extracellular LDL and
VLDL, respectively, to receptors and VLDL to LDL delipidation with a constant source of VLDL.
Equations (12) and (15) describe bound LDL and VLDL formation, unbinding and internalisation,
respectively, whilst Equations (13) and (16) detail the internalisation of LDL and VLDL bound pits and
their respective breakdown. Equations (17) and (18) describe free and internalised receptor dynamics,
whilst Equations (19) and (20) detail endogenous and exogenous cholesterol regulation, the latter the
effect of cholesterol binding/unbinding to free SREBP-2.
The scaling parameters J and W are ratios representing the difference in volume between the
compartments in which the reactions take place. The nucleus of the cell constitutes approximately
10% [16] of the volume of the total cell and thus we set J = 0.1. We assume the volume
surrounding the cell is considerably greater than that of the cell, which from Jackson et al. [17] gives
W ≈ 1.5× 103. This accounts for the proportional concentrations between the three compartments:
serum, cell and nucleus.
Processes 2018, 6, 134 8 of 34
Many of the initial conditions are set equal to zero in order to help understand if the overall
system response is in agreement with the known biological behaviour and are given by
g¯h(0) = g¯h0, g¯r(0) = g¯r0, s¯(0) = s¯0, s¯bh(0) = 0, s¯br(0) = 0
m¯h(0) = m¯h0, m¯r(0) = m¯r0, h¯(0) = h¯0, l¯E(0) = l¯E0, l¯RB(0) = 0,
l¯I(0) = 0, v¯E(0) = v¯E0, v¯RB(0) = 0, v¯I(0) = 0, r¯ f (0) = r¯ f0,
r¯I(0) = 0, c¯(0) = 0 and c¯b(0) = 0.
(21)
2.2. Model Reduction
Our model consists of 18 coupled linear and non-linear ODEs. We now seek to reduce the number
of equations by application of the quasi-steady state approximation and conservation laws as detailed
in Appendix A. This reduces the number of equations to 12 such that
J
dm¯h
dt¯
=
µ¯∗mh
1 +
(
κ¯mh(1+(
c¯
K¯c
)xc )
s¯0
)xh − δ¯mhm¯h, (22)
J
dm¯r
dt¯
=
µ¯∗mr
1 +
(
κ¯mr(1+( c¯K¯c )
xc )
s¯0
)xr − δ¯mrm¯r, (23)
dh¯
dt¯
= µ¯hm¯h − δ¯h h¯, (24)
W
dl¯E
dt¯
= −α¯L r¯ f l¯E + α¯−L l¯RB +Wχ¯vv¯E, (25)
dl¯RB
dt¯
= α¯L r¯ f l¯E − α¯−L l¯RB − β¯L l¯RB, (26)
dl¯I
dt¯
= β¯L l¯RB − γ¯L l¯I , (27)
W
dv¯E
dt¯
= −α¯v r¯ f v¯E + α¯−vv¯RB −Wχ¯vv¯E +Wω¯, (28)
dv¯RB
dt¯
= α¯v r¯ f v¯E − α¯−vv¯RB − β¯vv¯RB, (29)
dv¯I
dt¯
= β¯vv¯RB − γ¯vv¯I , (30)
dr¯ f
dt
= γ¯r r¯I − Pβ¯0r¯Pf −ml β¯L
(
r¯ f l¯RB
r¯ f0 − r¯ f
)
−ml α¯L l¯E r¯ f +ml α¯−L l¯RB
−mv β¯v
(
r¯ f v¯RB
r¯ f0 − r¯ f
)
−mvα¯vv¯E r¯ f +mvα¯−vv¯RB, (31)
dr¯I
dt
= µ¯rm¯r − γ¯r r¯I + P f β¯0r¯Pf + f ml β¯L l¯RB
(
1 +
r¯ f
r¯ f0 − r¯ f
)
+ f mv β¯vv¯RB
(
1 +
r¯ f
r¯ f0 − r¯ f
)
, (32)
dc¯
dt¯
= RcholL γ¯L l¯I + R
chol
v γ¯vv¯I + µ¯c h¯− δ¯c c¯, (33)
with the initial conditions
m¯h(0) = m¯h0, m¯r(0) = m¯r0, h¯(0) = h¯0, l¯E(0) = l¯E0,
l¯RB(0) = 0, l¯I(0) = 0, v¯E(0) = v¯E0, v¯RB(0) = 0, (34)
v¯I(0) = 0, r¯ f (0) = r¯ f0, r¯I(0) = 0 and c¯(0) = 0.
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2.3. Non-Dimensionalisation
The model was non-dimensionalised according to the following rescalings
t¯ = t
δ¯mh
, m¯h = s¯0mh, m¯r = s¯0mr, h¯ = s¯0h, l¯E = l¯E0lE,
l¯RB = l¯E0lRB, l¯I = l¯E0lI , v¯E = v¯E0vE, v¯RB = v¯E0vRB, v¯I = v¯E0vI , (35)
r¯ f = r¯ f0r f , r¯I = r¯ f0rI , c¯ = c¯Tc,
where cT = 1.89× 1019 molecules/mL and s0 = 8.21× 1016 molecules/mL are the total concentrations
of cholesterol and SREBP-2 in a hepatocyte [12,18], respectively. Substituting these rescalings into
Equations (22)–(34) leads to
J
dmh
dt
=
µmh
1 +
(
κmh(1 + ( cκc )
xc)
)xh − δmhmh, (36)
J
dmr
dt
=
µmr
1 +
(
κmr(1 + ( cκc )
xc)
)xr − δmrmr, (37)
dh
dt
= µhmh − δhh, (38)
W
dlE
dt
= −αLr f lE + α−LlRB +WχvρvvE, (39)
dlRB
dt
= αLr f lE − α−LlRB − βLlRB, (40)
dlI
dt
= βLlRB − γLlI , (41)
W
dvE
dt
= −αvr f vE + α−vvRB −WχvvE +Wω, (42)
dvRB
dt
= αvr f vE − α−vvRB − βvvRB, (43)
dvI
dt
= βvvRB − γvvI , (44)
dr f
dt
= γrrI +
ml
ϑl
(
−βL
r f lRB
1− r f − αLlEr f + α−LlRB
)
−β0rPf +
mv
ϑv
(
−βv
r f vRB
1− r f − αvvEr f + α−vvRB
)
, (45)
drI
dt
= −γrrI + f β0rPf + f
ml
ϑl
(1 +
r f
1− r f )βLlRB
+ f
mv
ϑv
(1 +
r f
1− r f )βvvRB + µrmr, (46)
dc
dt
= RcholL σlγLlI + R
chol
v σvγvvI + µch− δcc, (47)
with the initial conditions
mh(0) = mh0, mr(0) = mr0, h(0) = h0, lE(0) = 1,
lRB(0) = 0, lI(0) = 0, vE(0) = vE0, vRB(0) = 0, (48)
vI(0) = 0, r f (0) = r f0, rI(0) = 0 and c(0) = 0.
All non-dimensional parameters in terms of dimensional ones and their values are shown in
Table 2.
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2.4. Parameter Estimation
We have utilised parameterisations detailed in [10,15] to inform each of the models, respectively.
Table 1 details each dimensional parameter, their value and source. Non-dimensional parameter values
and their definitions (in terms of dimensional ones) are given in Table 2.
In the case of the additional reactions involving LDLR synthesis (LDLR transcription, translation,
mRNA degradation and the dissociation of SREBP-2 for the LDLR gene) these were determined in
a similar manner to that detailed in [10] with further details provided in Appendix B. The rates of
VLDL and LDL delipidation and the source of extracellular VLDL were calculated as also shown in
Appendix B.
Initially the integrated model was informed with the parameter values detailed in [10,15] and
derived in Appendix B. A local sensitivity analysis was then used to determine which parameters
required variation such that the integrated model reproduced known intracellular cholesterol
concentrations [12]. Where adjustments to parameter values determined in [10,15] where made,
this is detailed in Table 1 (denoted “This study" along with either the citing of [10,15]) and Appendix B.
Table 1. Dimensional model parameters. Molec. denotes molecules, r receptors and conc. concentration.
Parameter Description Dimensional Value Units Reference
µ∗mh Rate of HMGCR mRNA transcription. 5.17× 105 molec.mL s [19,20]
µ∗mr Rate of receptor mRNA transcription. 4.56× 106 molec.mL s [19,21]
µh Rate of HMGCR translation. 3.32× 10−2 1s [20,22]
µc Rate of cholesterol production. 2.16× 103 1s [23–25]
µr Rate of receptor translation. 5.10× 10−1 1s [26]
δmh Rate of HMGCR mRNA degradation. 4.48× 10−5 1s [27]
δmr Rate of receptor mRNA degradation. 4.48× 10−5 1s [28]
δh Rate of HMGCR degradation. 6.42× 10−5 1s [29]
δc Rate of cholesterol degradation. 1.20× 10−4 1s This study.
κmh SREBP-HMGCR gene binding affinity. 8.21× 1016 molec.mL This study.
κc Cholesterol-SREBP-2 dissociation constant. 8.91× 1018 molec.mL This study.
κmr LDLR gene-SREBP-2 dissociation constant. 8.21× 1016 molec.mL This study.
αL Rate of LDL-receptor binding. 6.66× 10−17 mLr s [30]
α−L Rate of LDL-receptor unbinding. 5.90× 10−4 1s [30]
αv Rate of VLDL-receptor binding. 9.32× 10−16 mLr s [15,17,31]
α−v Rate of VLDL-receptor unbinding. 2.95× 10−4 1s [15,17]
βL Rate of LDL internalisation. 2.70× 10−3 1s [30,32,33]
βv Rate of VLDL internalisation. 2.70× 10−3 1s [15]
β0 Rate of free receptor internalisation. 0
mL(P−1)
r(P−1)s
[34]
γL Rate of LDL to cholesterol conversion. 3.33× 10−3 1s [33]
γv Rate of VLDL to cholesterol conversion. 3.33× 10−3 1s [15]
γr Rate of receptor recycling. 1.00× 10−2 1s [30]
χv Rate of VLDL-LDL delipidation. 8.7× 10−6 1s [35]
Ml Receptors covered by bound LDL. 1 [32]
Mv Receptors covered by bound VLDL. 2 [15]
P Number of receptors per pit. 180 [15]
f Fraction of receptors recycled. 0.7 [36]
RcholL Average cholesterol content per LDL. 3400 [37]
Rcholv Average cholesterol content per VLDL. 3100 [17]
J Nucleus to cell ratio. 0.1 [16]
W Cell medium to cell volume ratio. 1.50× 103 [15]
xc Molec. of cholesterol to inactivate SREBP-2. 4 [12]
xh Number of binding sites for SREBP-2 on HMGCR gene. 3 [12]
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Table 1. Cont.
Parameter Description Dimensional Value Units Reference
xr Number of binding sites for SREBP-2 on receptor gene. 1 [12]
ω Influx of extracellular VLDL. 6× 107 molec./mL This study.
mh0 Initial HMGCR mRNA conc. 3.0× 109 molec./mL This study [10]
mr0 Initial LDLR mRNA conc. 5.0× 109 molec./mL [38]
h0 Initial HMGCR conc. 9.04× 1011 molec./mL This study/[10]
lE0 Initial extracellular LDL conc. 1.17× 1013 molec./mL [15,17]
vE0 Initial extracellular VLDL conc. 2.95× 1012 molec./mL [15,17]
r f0 Initial unbound receptor conc. 3.27× 1013 molec./mL [15,30]
Table 2. Table of non-dimensional parameters including their definition and value.
Parameter Description Definition Non-Dimensional Value
µmh Rate of HMGCR mRNA transcription.
µ∗mh
s0δmh
1.406× 10−7
µmr Rate of receptor mRNA transcription.
µ∗mr
s0δmh
1.240× 10−6
µh Rate of HMGCR translation.
µh
δmh
7.4011× 102
µr Rate of receptor translation.
µrs0
δmhr f 0
2.876× 107
µc Rate of cholesterol synthesis.
µc
δmh
2.099× 105
κmh HMGCR DNA-SREBP-2binding affinity.
κmh
s0 1
κmr Receptor DNA-SREBP-2binding affinity. κmrs0 1
κc SREBP-Cholesterol dissociation constant. κcc0 4.714× 10−1
δmh Rate of HMGCR mRNA degradation.
δmh
δmh
1
δmr Rate of receptor mRNA degradation. δmrδmh
1
δh Rate of HMGCR degradation.
δh
δmh
1.433
δc Rate of cholesterol degradation. δcδmh
2.679
αL Rate of receptor-LDL binding.
αLr0
δmh
4.846× 101
α−L Rate of receptor-LDL unbinding.
α−L
δmh
1.317× 101
αv Rate of receptor-VLDL binding.
αvr0
δmh
6.782× 102
α−v Rate of receptor-VLDL unbinding. α−vδmh 6.585
βL Rate of LDL internalisation.
βL
δmh
6.027× 101
βv Rate of VLDL internalisation.
βv
δmh
6.027× 101
β0 Rate of empty pit internalisation.
Pβ0r
P−1
0
δmh
0
γL Rate of LDL-cholesterol conversion.
γL
δmh
7.440× 101
γv Rate of VLDL-cholesterol conversion.
γv
δmh
7.440× 101
γr Rate of receptor recycling.
γr
δmh
2.232× 102
χv Rate of VLDL-LDL breakdown.
χv
δmh
1.94× 10−1
ω Influx of extracellular VLDL. ω
δmhvE0
4.540× 10−1
ϑl Ratio of initial free receptors to initial extracellular LDL.
r f0
lE0
2.786
ϑv Ratio of initial free receptors to initial extracellular VLDL.
r f0
vE0
1.105× 101
σl
Ratio of initial extracellular LDL to intracellular
cholesterol concentration.
lE0
c0
6.190× 10−7
σv
Ratio of initial extracellular VLDL to to intracellular
cholesterol concentration.
vE0
c0 1.561× 10−7
ρv Ratio of extracellular VLDL to LDL concentration.
vE0
lE0
2.521× 10−1
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Table 2. Cont.
Parameter Description Definition Non-Dimensional Value
mh0 Initial HMGCR mRNA concentration.
mh0
s0 3.65 ×10−8
mr0 Initial LDLR mRNA concentration. mr0s0 6.09 ×10−8
h0 Initial HMGCR concentration. h0s0 1.10× 10
−5
vE0 Initial extracellular VLDL concentration
v0
v0 1
r f0 Initial free receptor concentration.
r f0
r f0
0.999
3. Results
3.1. Numerical Simulations
The system of Equations (36)–(48), parameterised with Table 1, was solved using the Matlab stiff
differential equation solver ODE15s, given the stiffness coefficient of the system was determined to be
λ = 143, 451. A plot of the simulation is shown in Figure 3. We have re-dimensionalised time on the
horizontal axis and run the system for approximately 175 h (until steady state) to capture the whole
range of behaviours exhibited.
The solutions in Figure 3 show initially (up to 10 h) HMGCR and receptor mRNA increase
in response to the initially low cholesterol levels which leads to an increase in HMGCR, internal
receptors and cholesterol. VLDL and LDL bind rapidly to free receptors, however VLDL molecules
bind more rapidly than LDL due to their greater binding affinity. The rapid binding of lipoproteins
leads to an increase in bound LDL and VLDL and hence internalised LDL and VLDL increase.
Intracellular cholesterol concentrations increase as cholesterol is extracted from the internalised
lipoproteins, and receptors are stored internally and recycled to the cell surface. As intracellular
cholesterol concentrations increase, the negative feedbacks from SREBP-2 inhibit HMGCR and LDLR
mRNA transcription and hence less HMGCR and LDLR are synthesised. This decrease activates the
feedforward/feedback mechanisms and the cell exhibits transient oscillatory type behaviour as a result
of the system dynamics.
After this initial period, the molecular components of the system settle to a stable steady-state
whilst the longer timescale events of VLDL and LDL endocytosis continue to occur. Eventually each
component of this part of the system settles down to a non-zero stable steady-state, a result of the
constant influx of VLDL to the system; extracellular VLDL settle before that of extracellular LDL given
delipidation and an increased receptor-molecule binding affinity for VLDL than LDL. Internalised
receptors tend to a non-zero steady state as the cell is constantly producing receptors to keep in the
internal store ready for insertion onto the cell surface.
The concentration of intracellular cholesterol increases initially as a result of the biosynthesis
cascade with cholesterol extracted from internalised VLDL and LDL having a significantly less impact
on cholesterol levels after the first 10 h.
3.2. Model Analysis
3.2.1. Steady-State Analysis
Given the occurrence of negative and positive feedbacks (genetic and whole cell scale) within
the system, we undertook a steady-state analysis of Equations (36)–(48) to understand how many
biologically feasible steady-states it may exhibit; more than one real, positive steady-state may indicate
more complex underlying system dynamics which have not been previously elucidated experimentally.
This analysis was conducted in the absence (ω = 0) and presence (ω 6= 0) of a source of VLDL particles.
In the case of ω = 0 we obtained the expected result that all of the extracellular lipoproteins are
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internalised and esterified, leading to an abundance of free receptors on the cell surface and LDLR and
cholesterol being produced via their respective biosynthetic pathways

m∗h
m∗r
h∗
l∗E
l∗RB
l∗I
v∗E
v∗RB
v∗I
r∗f
r∗I
c∗

=

µmh
δmh
1+
κmh
1+
 µcµhm
∗
h
δhδc
κc

4


3
µmr
δmr
(
1+κmr(1+ c
∗
κc )
4
)
µhm∗h
δh
0
0
0
0
0
0
P
√
γrr∗I
β0
µrm∗r
γr(1− f )
µcµhm∗h
δhδc

, (49)
where the ∗ notation indicates steady-state. This result was also verified numerically.
Figure 3. Numerical simulation of Equations (36)–(48). Initially mRNA levels increase in response
to zero cholesterol in the system, which leads to an increase in HMGCR and internal receptor levels.
VLDL and LDL bind to receptors and are internalised where cholesterol is extracted. The increase in
HMGCR and extraction of cholesterol from internalised lipoproteins cause intracellular cholesterol
concentrations to increase. Damped oscillations can be seen as HMGCR mRNA responds to changing
cholesterol concentrations and the receptor mechanism responds accordingly. Following this initial
transient behaviour, the molecular and cholesterol parts of the system settle to a relatively stable
steady-state whilst VLDL and LDL continues to be extracted from the extracellular environment until a
final steady-state is reached.
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In the case of ω 6= 0 the system of equations could only be reduced to the four state system of(
1− 1
f
)
γrr∗I +
ml
ϑl
ρv(Wω− γvv∗I )
(
1− (α−L + βL) + α−LβL
)
+
mv
ϑv
γvv∗I
(
1− (α−v + βv)
βv
+
α−v
βv
)
+
µrµmr f2(c∗)
δmr
= 0, (50)
−γrr∗I +
f ml
ϑl
(
1 +
r∗f
1− r∗f
)
ρv(Wω− γvv∗I ) +
f mv
ϑv
(
1 +
r∗f
1− r∗f
)
γvv∗I
+
µrµmr f2(c∗)
δmr
= 0, (51)
γrr∗I +
ml
ϑl
ρv(Wω− γvv∗I )
( −r∗f
1− r∗f
− (α−L + βL) + α−LβL
)
+
mv
ϑv
γvv∗I
( −r∗f
1− r∗f
− (α−v + βv)
βv
+
α−v
βv
)
= 0, (52)
RcholL σlρv(Wω− γvv∗I ) + Rcholv σvγvv∗I +
µcµhµmh f1(c∗)
δhδmh
− δcc∗ = 0, (53)
where
f1(c) =
1
1 +
(
κmh
(
1 +
(
c∗
κc
)xc))xh
and
f2(c) =
1
1 +
(
κmr
(
1 +
(
c∗
κc
)xc))xr .
This system was then solved numerically in Maple (Version 2016.2) informed by the parameter
values given in Table 2. Only one steady-state was determined and the values obtained were found to
concur with the steady-states obtained in Figure 3.
3.2.2. Sensitivity analysis
Sensitivity analysis was conducted to determine how the output of our model can be apportioned
to the varying sources of input. We conducted local sensitivity analysis, varying each parameter
100-fold above and below its initial value, whilst keeping all the other variables constant as shown
in Table 2. We quantitatively measured, primarily, the effect of mechanisms on the steady state
intracellular cholesterol concentrations whilst also looking for significant variations in key elements of
the system, for example extracellular LDL levels which are an indicator of risk in CVD. What follows
is a summary of our findings with more details provided in Appendix C.
Sensitivity analysis of our fully integrated model demonstrated that the respective components
(cholesterol biosynthesis and endocytosis) reproduced similar effects on intracellular cholesterol
levels as they did when considered in isolation. For instance the integrated model shows the same
competition effect between LDL and VLDL for LDLR as detailed in [13,15]; a result of VLDL having
a greater receptor binding affinity than LDL. Likewise, this behaviour can be exacerbated by the
number of receptors occluded by a bound lipoprotein and by the rate of receptor synthesis. However,
where there are limited binding sites on the cell surface, smaller LDL particles are able to bind in spaces
that larger VLDL are unable to. We found that variation in parameters affecting LDLR synthesis does
not greatly affect cholesterol levels.
We found that biosynthesis of cholesterol has a greater effect on cellular cholesterol levels than
the uptake of extracellular lipoproteins, which agrees with the known biology [3]. The concentration
of free LDLR does not greatly affect intracellular cholesterol levels, but does have a much greater
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effect on the concentration of extracellular LDL and VLDL, both of which are major risk factors for
health conditions such as CVD. Therefore we know the receptor mechanism plays an important role in
lipoprotein clearance which agrees with experimental evidence [39].
The amount of cholesterol within an LDL or VLDL molecule (Rcholl , R
chol
v ) was found to have
very little effect on intracellular cholesterol levels. However, when Rcholl and R
chol
v were increased,
the concentration of HMGCR mRNA and LDLR mRNA were reduced. For 10-fold increased cholesterol
in VLDL, HMGCR mRNA was reduced by nearly 20% and receptor mRNA reduced by around
5%. To induce similar levels of mRNA reduction, the cholesterol content of LDL needs to be
increased 100-fold. This is due to the increased amount of cholesterol being brought in to the cell
via receptor mediated endocytosis and shows very tight genetic regulatory control of intracellular
cholesterol concentrations.
We have also found for certain values that parameters linked with cholesterol and receptor
biosynthesis (µmh, µh, µc, κmh, δmh, µmr, µr, J, xh and xc) can produce damped periodic behaviour;
the damping a result of the difference in the volumes of the cell nucleus and cytoplasm.
Sensitivity analysis of the VLDL-LDL delipidation parameter, χv, provided some interesting
results. Increasing the rate of delipidation results in a 40% decrease in extracellular VLDL
concentrations, but a 450% increase in extracellular LDL concentrations. Conversely, however, a 10-fold
decrease in the delipidation rate produces around an 8% increase in extracellular VLDL concentrations
but, significantly, nearly a 90% decrease in extracellular LDL concentrations. Furthermore, there is no
other significant changes in the rest of the system due to the perturbation of χv. Our model would
suggest, then, that delipidation of VLDL to LDL would be a good candidate as a target for LDL
reduction therapies.
3.3. Investigating Familial Hypercholesterolaemia (FH)
In this section we investigate whether our model is able to reproduce the known effects of the
disease Familial Hypercholesterolaemia (FH), the aetiology of which is well known. By altering specific
model parameters we can quantitatively represent the effect of genetic mutations on extracellular
VLDL and LDL levels.
FH is a genetic disorder, primarily of the LDL receptor gene and is characterised by high levels of
circulating LDL cholesterol. In certain populations (including French and Canadians) 1 in 67 people
suffer FH, with an increased risk of heart disease 20 times greater than non-sufferers [40]. Furthermore,
almost all people with FH will require plasma cholesterol-lowering drugs.
The gene pertaining to the LDL receptor is located on chromosome 19 and a number of mutations
have been identified in the DNA of individuals affected by this disorder [41]. Hobbs et al. [42]
identified five categories of LDL receptor defects, which are listed in Table 3 with a description of the
biological traits and parameters in our model that are affected. We will model each case by multiplying
each relevant parameter by 0, 0.2, 0.4 and 1. We are unable to model type II since our model does not,
with the exception of the nucleus and cytoplasm, sub-compartmentalise the cell.
Table 3. Familial hypercholesterolaemia class types and their relation to parameters in our model.
Class Description Parameter Affected
I LDLR not synthesised. µmr
II LDLR not transported to the golgi apparatus.
III LDL-LDLR binding ineffective. αL
IV Bound LDL not internalised properly. βL
V Receptors not recycled effectively. f
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3.3.1. Class I FH
Let us first consider Class I where LDL receptors are not synthesised. In this case the associated
parameter is µmr, which we vary in order to investigate the model response. The results illustrated
in Figure A1 show how the inhibition of receptor synthesis prolongs uptake of extracellular LDL,
which would equate to higher circulating plasma LDL levels.
As expected, with µmr = 0, receptor numbers deplete and lipoproteins are unable to be
internalised. Levels of extracellular VLDL increase because of continuous influx, as do LDL as
VLDL are broken down into LDL. This increase in extracellular LDL concentration biologically would
increase the risk of health problems. When varying µmr successively we find that even a small increase
in the number of receptors synthesised decreases the levels of extracellular LDL and VLDL. For instance
increasing the value from 0 to 20% of normal function halves the concentration of circulating VLDL and
LDL. Increasing the value from 0 to 40% of normal function decreases the concentration of circulating
VLDL and LDL by 80–90%, respectively.
3.3.2. Class III FH
We now consider Class III where binding of LDL and receptors is ineffective. In this case the
associated parameter is αl (LDL receptor binding), which we vary in order to investigate the model
response. The results are illustrated in Figure A2 and show that the amount of extracellular LDL
is affected significantly by the inability of LDL to bind to LDLR on the cell surface. We can see
that increasing LDL-LDLR binding from 0 to just 20% of normal function decreases extracellular
LDL concentrations by 67%. Subsequently restoring normal function reduces extracellular LDL
concentrations by nearly 97%.
3.3.3. Class IV FH
Here LDL bound to receptors on the cell surface are not internalised properly. In this case we vary
the associated parameter, βl and investigate the model response. The results illustrated in Figure A3
demonstrate the concentration of extracellular LDL is significantly affected if βl = 0, but is only
marginally altered if βl is increased. There is also a significant difference between the amount of
bound LDL when βl = 0 and when βl is increased, however this does not appear to significantly affect
extracellular VLDL concentrations. Aside from when βl = 0, the system is fairly robust to changes in
the internalisation rate of bound LDL particles.
3.3.4. Class V FH
Finally we consider Class V where LDL receptors are not recycled effectively. To investigate
this case we vary the associated parameter f . The results in Figure A4 show the number of free and
internalised receptors declines significantly for reduced receptor recycling which causes an increase
in extracellular concentrations of LDL and VLDL. However the number of bound and internalised
VLDL is not affected as significantly as the number of bound and internalised LDL. This is because
VLDL have a greater binding affinity and so are more successful in binding competition. We also see a
reduction by more than half in both free and internalised receptor concentrations between the usual
value f = 0.7 and altered values f ≤ 0.7.
3.3.5. Individual Class FH Summary
Having explored the effects of different classes of FH, we have found that Class I has the greatest
effect on extracellular LDL and Class IV the least.
The lack of variation in intracellular cholesterol, HMGCR mRNA and HMGCR levels suggest
that despite the effects of FH, the cell is able to maintain intracellular cholesterol levels genetically.
This makes sense as without this control the concentration of cholesterol may decline to cytotoxic
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levels and the cell perish. However we know that humans are able to survive with FH indicating their
cells do not perish.
We now wish to simulate the effects of being afflicted with a combination of all four cases.
3.3.6. Combined FH
We used Latin Hypercube Sampling [43], to consider the possible outcomes for a range of
combined effects of FH Class types I, III, IV and V. Latin Hypercube Sampling generates a sample of
plausible collections of parameter values from a multidimensional distribution. The method takes
the midpoint of each quartile for parameters selected and randomly samples the combination of the
effects of the four FH class types. In this case this leads to the four hypothetical combined FH cases
detailed below.
FH Combined Case 1—(62.5% of µmr, 12.5% of αL, 87.5% of βL, 87.5% of f ),
FH Combined Case 2—(87.5% of µmr, 62.5% of αL, 37.5% of βL, 12.5% of f ),
FH Combined Case 3—(12.5% of µmr, 37.5% of αL, 62.5% of βL, 37.5% of f ),
FH Combined Case 4—(37.5% of µmr, 87.5% of αL, 12.5% of βL, 62.5% of f ).
Figure 4 provides a summary of the effects of each of the combined cases of FH on HMGCR mRNA,
HMGCR, LDLR mRNA, extracellular LDL and VLDL and cellular cholesterol levels. For completeness
full model results are provided in Appendix E . These lead to a disruption in receptor production,
free receptors, extracellular levels of VLDL and LDL and the binding and internalisation of VLDL and
LDL that we would expect to see as a result of the disease. Our model shows that despite lipoprotein
uptake being significantly reduced, the cell will keep intracellular cholesterol levels within a tightly
controlled range as a result of genetic regulation via the SREBP-2 cholesterol feedback. This feedback
ensures the cell responds to low levels of cholesterol by upregulating cholesterol biosynthesis, allowing
it to produce around 80% of the cholesterol the cell needs, in spite of disruptions to receptor function.
Whilst direct comparison with experimental values of intracellular cholesterol is not possible due to a
lack of reported values in the literature, we postulate here that this effect could be tested experimentally
via a series of VLDL and LDL uptake experiments. For populations of cells each affected by the different
FH classes, the relative difference in the uptake of the lipoproteins could be compared to that of a
control group of cells, in order to discern the differences detailed here.
From these model results we can infer the increased susceptibility to CVD events, as a result of
FH leading to increased plasma LDL levels concurs with the known biology. Furthermore, we can see
from the samplings taken, Case 3 leads to the greatest rise in plasma LDL levels, due to low receptor
synthesis and recycling combined with that of low LDL receptor binding affinity.
3.4. Modelling Statin Therapy
We can also consider if our model produces the known biological response to statins, globally the
most commonly used pharmaceutical treatment for lowering plasma cholesterol levels. These drugs
competitively bind to HMGCR preventing binding with HMGCoA and so inhibiting cholesterol
biosynthesis. This reduces intracellular cholesterol concentrations thereby up-regulating receptor
synthesis which clears more lipoproteins from the circulation. In this model, the effect of taking statins
can be modelled by modifying the transcription of HMGCR mRNA, µmh. We here show the numerical
results for an idealised statin that instantaneously halts transcription of HMGCR mRNA, for 11 doses
over a period of 7 days such that
µmh =
{
0, for approx. 9 h 45 m + n× 14 h 45 m ≤ t ≤ 23 h + n× 14 h 45 m,
1.406× 10−7, otherwise,
where n is the number of dosage periods. Although this is a dramatic change in µmh it is sufficient to
show that the model replicates the expected dynamical behaviour. We have run the model to steady
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state and begun our simulation from that point. At time t = 9 h 45 m we set µmh = 0 for the equivalent
of approximately 13 h. Dosing in this way, the solutions give a 17.6% reduction in extracellular LDL.
No further discernible differences in extracellular LDL levels were perceived after this period.
Figure 4. Familial Hypercholesterolaemia combined effects on HMGCR mRNA, HMGCR, LDLR
mRNA, extracellular LDL and VLDL and cellular cholesterol levels. Results for all model variables are
given in Appendix E.
It is indicated that in general statins cause a 25%–55% decrease in LDL-cholesterol [44]. We were
able to achieve a 25% reduction in extracellular concentrations by setting the rate of receptor mRNA
transcription µstatinmr = 0.3 × µmr, with the same 11 doses over 7 days. The solutions in Figure 5
show that upon receiving a statin dose, levels of HMGCR mRNA and HMGCR decline to zero as
transcription is inhibited. Solutions for all model variables are provided in Appendix F. Due to
the lack of biosynthesis, cholesterol levels also decline dramatically which in turn up-regulates the
transcription of receptor mRNA; a response by the cell to bring more cholesterol in to maintain healthy
levels. Subsequently we see a rise in internal receptor levels and hence free receptors on the cell
surface. Extracellular LDL and VLDL decrease as they bind to the abundant free receptors and are
endocytosed. We see that with each statin dose extracellular LDL concentrations gradually decline for
7 days until they level out at a 25% decrease. Whilst of the same order of magnitude as that observed
clinically we believe differences are a result of the short term duration of our statin application versus
the longer term scale of measurements taken in patients (e.g. weeks or months). Furthermore, our
model does not contain a detailed description of other elements of lipoprotein metabolism, for instance
chylomicrons, or that of VLDL production by the hepatocyte. LDL levels are also directly linked to
those of VLDL at present, whereas in vivo it is known they do not vary as much as other lipoproteins
postprandially [45].
After 168 h (7 days) we allow µmh to return to its steady-state value of 1.406× 10−7. In doing so
concentrations of each of the two biosynthesis pathways (cholesterol and LDLR) exhibit periodic
overshoot type behaviour as the system returns to its pre-stimulus steady-state; a result of the
homoclinic Hopf bifurication behaviour that the cholesterol biosynthesis pathway exhibits [10].
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Those entities directly affected by this change, for example receptor synthesis, also exhibit such
behaviour, but this is dampened in the case of bound VLDL and LDL and considerably more so in the
case of their extracellular levels.
Figure 5. A simulation showing the effect of statin therapy on our integrated model of cholesterol
metabolism. Here 11 doses are applied over a seven day period starting at approximately t = 10 h.
The inhibition of HMGCR mRNA transcription subsequently decreases HMGCR and cholesterol
biosynthesis which up-regulates receptor mRNA transcription and receptor synthesis, which leads to a
reduction in extracellular LDL and VLDL levels. A complete set of model solutions are provided in
Appendix F.
4. Discussion and Conclusions
In this paper we have formulated, solved and analysed a nonlinear deterministic ODE model
describing the key mechanisms of hepatocyte endocytosis of VLDL and LDL coupled with a description
of cholesterol and receptor biosynthesis via the HMGCR pathway.
Parameterised with data from the relevant literature, the model was solved using the Matlab
stiff differential equation solver ODE15s. Solutions showed the system synthesising cholesterol
and receptors in response to mRNA transcription and translation of each entity, and uptake of
extracellular VLDL and LDL as a result of receptor synthesis and the extraction of cholesterol from
internalised lipoproteins.
Sensitivity analysis showed that the model qualitatively reproduced the known biology of
lipoprotein uptake and receptor and cholesterol regulation [17,30,33]. It highlighted the competition
effect between LDL and VLDL when binding to free receptors on the cell surface. VLDL have a greater
binding affinity than LDL and so are removed from the lipoprotein rich medium faster than LDL.
However, we found that when receptor numbers were reduced, LDL particles are able to bind in
spaces that VLDL are not able to, given their differences in sizes, and thus extracellular LDL levels
decrease faster than VLDL ones. We found the concentration of free receptors on the cell surface
for lipoproteins to bind to have little effect on intracellular cholesterol levels but greatly impacted
concentrations of extracellular LDL and VLDL which is a major risk factor for health problems such
as CVD. Sensitivity analysis also demonstrated that periodic behaviour exhibited by the cholesterol
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biosynthesis system [12] becomes damped as the signal dissipates from transcription in the cell nucleus
to translation in the cell cytoplasm.
Our work has highlighted that small changes in the rate of VLDL to LDL delipidation had
significant effects on extracellular LDL concentrations but not the rest of the system. Hence this process
could be a good candidate target for LDL reductive therapies. While modelling processes in this way
is helpful to identifying possible new methods of treatments, the enzymes responsible for this reaction
(lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein) have dual functions which are
not represented by our model, so it is hard to predict the full extent of including this change without
further work.
Our model demonstrates that cholesterol biosynthesis is the dominant source of cholesterol for the
cell. Thus any major disruption of this pathway is likely to have a detrimental effect on human health.
Thus whilst any therapy targeted at reducing intracellular cholesterol, such as statins, will favourably
decrease plasma levels of circulating lipoproteins in time, our model results suggest the counteracting
of any decrease in intracellular cholesterol is limited by the number of receptors available on the cell
surface (a function of the cell size and receptor internationalisation and recycling) and their rate of
internalisation. Hence in cases where cholesterol biosynthesis is compromised we speculate it will be
difficult to supplement intracellular cholesterol levels via increases in plasma cholesterol levels alone.
Although the mathematical formulation of lipoprotein endocytosis used here assumes the
surface of the cell is covered in a continuum of LDLR [15], the main outcome of the model
(total cholesterol content) does not greatly differ to that of [12] in respect of predicting each class
of Familial Hypercholesterolaemia and statin therapy. We, however, note the differences between each
of [13,15] at the lower level detail of receptor occupancy levels and rate of lipoprotein uptake require
further investigation.
We have been able to explore the effects of the genetic disease Familial Hypercholesterolaemia
and statins using our integrated model of cholesterol metabolism. We found that Case I FH has the
greatest effect on extracellular LDL concentrations and Case IV the least. The effects of combined
cases were shown to affect receptor mRNA, free and internalised receptor levels and the extracellular
concentrations of LDL and VLDL. We also found the model replicates the qualitative effects of statins
very closely.
Quantitatively the model produced a 25% reduction in extracellular LDL levels for repeated
statin dosing over a seven day period when the receptor mRNA transcription rate was decreased by
70%. Whilst our the model was able to reproduce the clinically reported lower bound of extracellular
LDL reductions following statin therapy, we believe improvement in this result could be made by
including a more thorough description of in vivo lipoprotein metabolism (e.g., chylomicrons, HDL)
and longer dosing periods. Thus we believe further model extensions coupled with clinically informed
parameterisation of this work are required to fully capture the quantitative regulation of lipoproteins
and their responses to statin therapy.
In conclusion, our work has demonstrated that mathematical modelling can provide a useful
tool for understanding the cellular (lipoprotein endocytosis) and subcellular (biosynthesis and genetic
regulation of cholesterol and receptors) processes that occur during lipoprotein metabolism. Whilst the
level of abstraction of our mathematical model is quite high, this work demonstrates that such
simplifications of a complex system can still reproduce the known biology of disease states and
therapeutic interventions. Future work and extensions to the model presented here is thus needed to
consider the effect of other aspects of the overall system, occurring at the subcellular and tissue level.
There thus remains scope for further testing and application of such models and their extension to
contexts that include a description of other dietary lipoproteins.
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Appendix A. Model Reduction
Equations (3)–(20) were reduced as follows. We first observe that the total number of genes with
a cell remains constant whether bound to SREBP-2 or otherwise. Adding Equations (3) and (6) for
HMGCR synthesis, and (4) and (6) for LDLR synthesis, respectively, and integrating with respect to
time leads to
g¯h + s¯bh = g¯h0 and g¯r + s¯br = g¯r0. (A1)
The total amount of SREBP-2 in a cell is also constant such that
s¯+ s¯bh + s¯br + c¯b = S¯0 ≈ s¯+ c¯b, (A2)
since s¯bh + s¯br  s¯+ c¯b.
We further reduce the system by assuming DNA-transcription factor binding is rapid in
comparison to the reaction events in the cell [10,46] and so reaches a steady state faster than the
rest of the system. This rapid equilibrium approximation applied to Equation (6) leads to
s¯bh ≈ g¯h0 s¯
xh
s¯xh + K¯xhmh
, (A3)
where K¯mh =
(
κ¯−mh
κ¯mh
) 1
xh .
Applying the same approximation to Equation (7) leads to
s¯br ≈ g¯r0 s¯
xr
s¯xr + K¯xrmr
, (A4)
where K¯mr =
(
κ¯−mr
κ¯mr
) 1
xr .
Substitution of result (A3) into Equation (8) gives
J
dm¯h
dt¯
=
µ¯mh g¯h0 s¯xh
s¯xh + K¯xhmh
− δ¯mhm¯h, (5.19a)
and similarly for result (A4) into Equation (9) we find
J
dm¯r
dt¯
=
µ¯mr g¯r0 s¯xr
s¯xr + K¯xrmr
− δ¯mrm¯r. (5.20a)
We can substitute both results (A3) and (A4) into Equation (5) to give, after cancelling,
ds¯
dt¯
=κ¯−c(s¯0 − s¯)− κ¯c c¯xc s¯. (5.16d)
Finally we assume that cholesterol-SREBP-2binding is rapid in comparison to other reaction
events in the cell [10] such that
κ¯−c(s¯0 − s¯)− κ¯c c¯xc s¯ ≈ 0,
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which upon rearranging yields
s¯ ≈ K¯
xc
c s¯0
c¯xc + K¯xcc
=
s¯0
1 + ( c¯K¯c )
xc
, (A5)
with K¯c =
(
κ¯−c
κ¯c
) 1
xc .
Using result (A5) we can express Equation (5.19a) in terms of c such that
J
dm¯h
dt¯
=
µ¯∗mh
1 +
(
K¯mh(1+(
c¯
K¯mh
)xc )
s¯0
)xh − δ¯mhm¯h. (5.19b)
with µ¯∗mh = µ¯mh g¯h0.
Similarly for (5.20a) we have,
J
dm¯r
dt¯
=
µ¯∗mr
1 +
(
K¯mr(1+( c¯K¯c )
xc )
s¯0
)xr − δ¯mrm¯r, (5.20b)
with µ¯∗mr = µ¯mr g¯r0.
Following the work in Tindall et al. [15] we seek to define the number of bound and occluded
receptors. Quantities of m˜l,v are dependent on the average occupancy of surface receptors. In high
levels of extracellular LDL and VLDL, average occupancy will be high and free receptors will be
low, hence fewer free receptors will be internalised with each pit and m˜l,v will have a small value.
Intuitively then, in low concentrations of extracellular LDL and VLDL, m˜l,v will have a larger value.
To simplify, we can assume the total number of receptors is approximately constant over shorter
time-scales, such as that of pit internalisation, then we can say the total number of receptors on the cell
surface is
r¯b + r¯ f = ml l¯RB +mvv¯RB + r¯ f ≈ r¯k, (A6)
where r¯b represents bound receptors.
We can also assume, as pits are internalised, a fraction of all receptors are internalised also,
given by
r¯b + r¯ f = ml l¯RB +mvv¯RB + m˜l(r¯ f )l¯RB + m˜v(r¯ f )v¯RB. (A7)
We assume the contribution of free receptor internalised with each particle is divided equitably
between all bound particles, that is m˜l(r¯ f ) = mlT(r¯ f ) and m˜v(r¯ f ) = mvT(r¯ f ) with T(r¯ f ) being the
total density of free receptors. We can find T(r¯ f ) by calculating the difference between Equations(A6)
and (A7) giving
T(r¯ f ) =
r¯ f
ml l¯RB +mvv¯RB
=
r¯ f
r¯ f0 − r¯ f , (A8)
where , since the number of internalised receptors is small, a suitable value for r¯k is r¯ f0
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Appendix B. Parameter Estimation
m¯r0—Initial value of receptor mRNA: Rudling et al. (2002) [38] details copy numbers of mRNA found
in human liver cells under basal conditions. We take a value of 48 copies of receptor mRNA per cell,
i.e. per 10−9 mL which gives 48 molecules/10−9 mL = 4.8×1010 molecules/ml. This value was then
refined using sensitivity analysis to give m¯r0 = 5.0× 109 molecules/mL.
µ¯mr —Rate of receptor mRNA transcription: As for µ¯mh, one human LDLR mRNA transcript is
5265 bases long [21]. To transcribe one molecule of LDLR mRNA, from one gene, at a rate of 12 bases
per second, takes
5265 bases
12 bases/s
= 438.75 s.
So per gene we have 1/438.75 s = 2.28 × 10−3 molecules/s. There are two genes in a liver cell so
4.56× 10−3 LDLR mRNA molecules are synthesised per cell per second. With a cell volume equal to
10−9 mL this gives 4.56×10−3 molecules/s / 1×10−9 mL giving µ¯mr = 4.56× 106 molecules/mL/s.
µ¯r—Rate of receptor translation: Soutar and Knight (1990) [19] tell us a human LDLR mRNA
transcript contains 839 amino acids. For one ribosome to transcribe one molecule of LDLR
protein, from one LDLR mRNA, at 6 amino acids per second, it takes 839 amino acids / 6 amino
acids/s = 139.83 s. Then per ribosome this gives
1 molecule
139.83 s
= 7.15× 10−3 molecules/s.
The coding region of LDLR mRNA is 839 amino acids × 3 = 2517 nucleotides long, and a
ribosome can attach every 35 nucleotides, so we have 71.91 ribosomes per mRNA molecule. Finally,
7.15×10−3 molecules/s/ribosome × 71.91 ribosomes gives µ¯r = 0.51 molecules/s.
δ¯mr—Rate of receptor mRNA degradation: In the absence of further details we assume the rate
of receptor mRNA degradation is equivalent to that HMGCR mRNA degradation and so take
δ¯mr = 4.48× 10−5 /s.
κ¯mr—Dissociation of SREBP-2 for receptor gene: Yang and Swartz (2011) [47] quantify DNA binding
affinities to other transcription factors at 54.2 nmol. We convert this value into units of molecules/mL
by the use of Avogadro’s constant, such that
100× 10−9 moles
1000 mL
× (6.022× 1023 molecules/mol) = 3.26× 1013 molecules/mL,
as an estimate we took K¯2 = O(1013). This value was then refined using sensitivity analysis to give
κ¯mr = 8.21× 1016 molecules/mL.
ω¯—Rate of VLDL synthesis: We estimated a value for the rate of VLDL synthesis as
ω¯ = 6.00× 107 particles/mL/s. This value was derived by a local sensitivity analysis such that model
reproduced known intracellular cholesterol concentrations.
xr—Number of binding sites on LDLR gene for SREBP-2: The number of binding sites on the
receptor gene available to SREBP-2 [12] is taken as being 1.
Appendix C. Sensitivity Analysis
Results of the local sensitivity analysis of Equations (36)–(48) showing the relative percentage
change from steady-state as each parameter was varied 100-fold below and above the values indicated
in Table 2. Here “mRNA H" is HMGCR mRNA, “LE" is extracellular LDL, “LRB" is receptor bound
LDL, “LI" is intenalised LDL, “VE" is extracellular VLDL, “VRB" is receptor bound VLDL, “VI" is
internalised VLDL, “RF" is free receptors and “RI" is internalised receptors. Green indicates a less than
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10% change from the steady-state value found when the model was solved using the values in Table 2,
yellow greater than 10% but less than 50% and pink greater than 50%.
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Appendix D. Familial Hypercholesterolaemia Analysis
Figure A1. Familial Hypercholesterolaemia Class I; LDLR are not synthesised correctly, affecting
parameter µmr. Results show a lack of receptors has a significant impact on extracellular LDL and
VLDL concentrations.
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Figure A2. Familial Hypercholesterolaemia Class III; binding of LDL to LDL receptors is ineffective,
affecting parameter αL. Results show a lack of LDL binding prevents LDL being endocytosed.
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Figure A3. Familial Hypercholesterolaemia Class IV; Bound LDL not internalised properly, affecting
parameter βL. Results show the lack of internalisation of bound LDL particles blocking LDL binding.
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Figure A4. Familial Hypercholesterolaemia Class V; receptors are not recycled properly, affecting
model parameter f . Results show a decrease in free and internalised receptors, significantly affecting
extracellular concentrations of both LDL and VLDL.
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Appendix E. Full Model Results for Combined Cases of Familial Hypercholesterolaemia
Figure A5. Familial Hypercholesterolaemia combined effects. Showing a combination of reduced
synthesis production and recycling and ineffective LDL binding and internalisation can dramatically
increase levels of circulating LDL and VLDL.
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Appendix F. Full Model Results for Statin Application
Figure A6. A simulation showing the effect of statin therapy on our integrated model of cholesterol
metabolism. Here 11 doses are applied over a seven day period starting at approximately t = 10 h.
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